Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Terminated 1Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 27Genitourinary 14Gynecologic 11Thoracic 4Endocrine 4Dermatologic 4CNS 4Breast 4NET 3Head & Neck 3Sarcoma 2Tumor-Agnostic 1Other hematologic neoplasm 1

Conditions

Neoplasms 2Brain Neoplasms 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Melanoma 1Glioblastoma 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Biliary Tract Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 73Temozolomide 68Specimen Handling 48Radiotherapy 40Radiosurgery 29Bevacizumab 26Radiation 25Cyclophosphamide 25Nivolumab 21Biopsy 21pembrolizumab 20Carboplatin 16X-Rays 14Lomustine 13Ipilimumab 13fludarabine 12Irinotecan 12Vincristine 11Topotecan 11Surgical Procedures, Operative 11Cisplatin 11Blood Specimen Collection 11trametinib 9dinutuximab 9Immunoglobulin G 8Etoposide 8Doxorubicin 8lutetium Lu 177 dotatate 7fludarabine phosphate 7atezolizumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
lenvatinib × CNS × 90 days × Clear all
NCT04955743 2026-06-04

Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma

Yale University

Phase 2 Terminated
18 enrolled 13 charts
CNSDermatologicGenitourinary

Brain Neoplasms, Carcinoma, Renal Cell, Melanoma

NCT03797326 2026-05-04

LEAP-005

Merck Sharp & Dohme LLC

Phase 2 Completed
611 enrolled 27 charts
BreastCNSGastrointestinalGynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Biliary Tract Neoplasms, Glioblastoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT05081180 2026-05-01

Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors

EMD Serono

Phase 1 Active not recruiting
17 enrolled
CNS

Neoplasms, Central Nervous System Neoplasms

NCT05064280 2026-04-16

Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases

M.D. Anderson Cancer Center

Phase 2 Recruiting
104 enrolled
CNS

Brain Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡